Interaction of HOXA9/MEIS1/PBX3 is responsible for hematopoietic system transformation in MLL-rearranged (MLL-r) leukemia. Of these genes, HOXA9 has been shown to be critical for leukemia cell survival, while MEIS1 has been identified as an essential regulator for leukemia stem cell (LSC) maintenance. Although significantly high expression of PBX3 was observed in clinical acute myeloid leukemia (AML) samples, the individual role of PBX3 in leukemia development is still largely unknown. In this study, we explored the specific role of PBX3 and its associated regulatory network in leukemia progression. By analyzing the clinical database, we found that the high expression of PBX3 is significantly correlated with a poor prognosis in AML patients. ChIP-Seq/qPCR analysis in MLL-r mouse models revealed aberrant epigenetic modifications with increased H3K79me2, and decreased H3K9me3 and H3K27me3 levels in LSCs, which may account for the high expression levels of Pbx3. To further examine the role of Pbx3 in AML maintenance and progression, we used the CRISPR/Cas9 system to delete Pbx3 in leukemic cells in the MLL-AF9 induced AML mouse model. We found that Pbx3 deletion significantly prolonged the survival of leukemic mice and decreased the leukemia burden by decreasing the capacity of LSCs and promoting LSC apoptosis. In conclusion, we found that PBX3 is epigenetically aberrant in the LSCs of MLL-r AML and is essential for leukemia development. Significantly, the differential expression of PBX3 in normal and malignant hematopoietic cells suggests PBX3 as a potential prognostic marker and therapeutic target for MLL-r leukemia.
there are over 50 identified MLL translocation partners encoding nuclear or cytoplasmic proteins with heterogeneous functions. The most common MLL fusion partners include AF4, AF9, ENL, AF10 and ELL, which together account for >80% of MLL-rearranged (MLL-r) AML.
2,3 MLL-NRIP3 is a recently reported MLL translocation and was demonstrated to be able to induce AML in mice in a previous study. 4 Despite various fusion partners, accumulating evidence suggests that many MLL-rearranged (MLL-r) leukemias might share similar mechanism(s) to transform leukemia, and the aberrant epigenetic regulatory network was considered as one of the most important mechanisms. 5, 6 Perturbation of the epigenome has been demonstrated to contribute to leukemogenesis and leukemia maintenance. The wild-type MLL gene encodes H3K4 methyltransferase and is responsible for the activation of HOXA genes. 7 MLL also plays a critical role in stem cell self-renewal in fetal liver and adult bone marrow. 8 Mostly, when translocated with its partner, MLL loses its SET domain (H3K4 methyltransferase domain). However, leukemia stem cells (LSCs) in MLL-r leukemia still exhibited high levels of H3K4me3 modification, which is crucial for maintenance of the LSC transcriptional programming. 5, 9 In addition, abnormal profiles of H3K79me2 (a histone mark associated with actively elongated genes) were found on MLL-AF9 fusion target loci in LSCs. 5, 10, 11 Targeting the H3K79me2 methyltransferase DOT1L could selectively impair the proliferation of MLL-fusion gene transformed cells as well as primary leukemic cells with MLL-translocation.
12-15
These data indicated that inhibition of aberrant epigenetic modification could be an effective approach for MLL-r AMLtargeted therapy. In addition to the abnormal epigenetic modification patterns in MLL-r AMLs, disordered downstream gene expression profiling also plays an important role in malignant transformation and leukemia progression. It was reported that high expression of homeobox genes such as HOXA9 and HOXA10 or cofactor MEIS1 is the hallmark of MLL-r leukemia. [16] [17] [18] MEIS1 belongs to the TALE (three-amino-acid loop extension) family, an atypical homeodomain protein family, and several TALE members have been reported to function as cofactors for HOXA genes. 19, 20 Importantly, enforced expression of HOXA9/MEIS1 could induce the transformation of a normal hematopoietic system to leukemia. 21, 22 Recently, arising evidence revealed the important role of other TALE family members such as TGIF1 and PBX3 in AML. [23] [24] [25] PBX3 have been proven to form a dimer with MEIS1 to evoke the full transforming activity of HOXA9.
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Most surprisingly, ectopic expression of both PBX3 and MEIS1 was sufficient to transform normal hematopoietic stem/progenitor cells (HSPCs) and induce AML in mice. 27 These data led us to hypothesize that TALE family members might play more significant roles than simply functioning as cofactors for HOXA genes in MLL-r leukemia.
Although it was demonstrated that co-expression of Pbx3 with either Meis1 or Hoxa9 is sufficient to transform normal murine HSPCs and to recapitulate the phenotype caused by ectopic expression of MLL-fusion genes, 24, 27 the specific role of PBX3 in MLL-r leukemia progression is largely unknown. In this study, we found that high expression levels of PBX3 were both in AML patient samples and in LSCs of MLL-r induced AML mouse models. Further study demonstrated that aberrant epigenetic modification with increased H3K79me2, decreased H3K9me3 and H3K27me3 levels in mice was associated with the abnormal expression profile. Using a CRISPR/Cas9-mediated knockout approach, we further explored the functional role of PBX3 in LSC maintenance in MLL-r leukemia.
Material and Methods
Mice C57BL/6 mice (8-10-weeks-old) were maintained at the specific pathogen-free animal facility of the State Key Laboratory of Experimental Hematology (SKLEH) institution. The experimental protocol was approved by the Institutional Animal Care and Use Committee of the Institute of SKLEH.
Generation of MLL-AF9 and MLL-NRIP3 leukemia mouse models
pMIG-MLL-AF9 and pMIG-MLL-NRIP3 plasmids were constructed as described previously. 4, 28 For retrovirus production, either pMIG-MLL-AF9 or pMIG-MLL-NRIP3 was cotransfected into the 293T packaging cell line with pCMV-VSVG and pKat. The supernatant medium containing viruses was collected 48 and 72 hrs after transfection and used to infect overnight-cultured c-Kit 1 cells, which were isolated from 8-to 10-week-old C57BL/6 mice using CD117 microbeads (Miltenyi, Auburn, CA). After 2 days of culture, infected cells were collected and transplanted into lethally irradiated (9.5 Gy) mice.
4,28
What's new? Acute myeloid leukemia (AML) with myeloid/lymphoid or mixed-lineage leukemia (MLL) translocation constitutes a group of aggressive hematopoietic malignancies. The mechanisms by which MLL rearrangements mediate leukemic transformation, however, are not fully understood. In the present study, poor prognosis in AML patients was associated with elevated expression of the pre-B-cell leukemia homeobox 3 (PBX3) gene. Moreover, PBX3 was found to be aberrantly regulated epigenetically in leukemia stem cells, while in leukemic mice, Pbx3 deletion significantly extended survival. The findings suggest that PBX3 serves a critical role in leukemia development and may be a potential prognostic marker for MLL-rearranged disease.
CRISPR/Cas9 mediated gene targeting
The Lenti-U6-sgRNA-SFFV-Cas9-2a-mCherry-wpre plasmid was used to knock out PBX3. 
ChIP-qPCR
Leukemia cells were collected from the bone marrow of either MLL-AF9 or MLL-NRIP3 AML mice, and normal bone marrow cells from wild type C57BL/6 mice were used as a control. c-Kit 1 cells were purified from leukemic or normal mice bone marrow by using CD117 microbeads. The following procedures were performed as described previously. 31 Simply, isolated cells were fixed with a final concentration of 1% formaldehyde for 10 min at room temperature, which was stopped by adding a final concentration of 0. 
Dot1L inhibitor treatment
EPZ004777 (Selleck chemical, S7353) stock solutions (10 mM) were prepared in DMSO and stored at 2208C. Serial dilutions of stock solutions were carried out just prior to use in each experiment and final DMSO concentration were kept at, or below 0.2%. MLL-AF9 quaternary recipient mice bone marrow cells were treated by 10 lM EPZ004777, 20 lM EPZ004777 or DMSO. 50000 leukemia cells were cultured in 24-well plate and the medium was refreshed every 3 days. Viable cells were counted every 3 days in the presence of EPZ004777 or DMSO vehicle control. After 15 days treatment, the cells were harvest to analyzed by immunoblotting and quantitative real-time PCR.
Complete blood counts analysis
Prepared 80 ll PBS (contained 2 mM EDTA) in 1.5 ml tube, and collected 20 ll peripheral blood from tail vein of mice. The blood samples were detected and analyzed by XT-2000i hematology analyzer (Sysmex).
Histology
Tissue samples were fixed in 4% formaldehyde over 12 hrs, then ethanol-dehydrated and extracted the ethanol with xylene. Embedded the samples in paraffin, and sectioned at 6-8 lm thickness using a microtome. Stained with hematoxylin and eosin.
Quantitative real-time PCR
RNA was extracted using the RNeasy Mini Kit (QIAGEN, 74106) according to the manufacturer's protocol. For quantitative PCR, first strand synthesis was performed using a cDNA reverse transcription kit (Takara, RR047A) according to the manufacturer's protocol. Quantitative PCR assays were performed in 96-well MicroAmp Fast Optical 96-Well Reaction Plates (Applied Biosystems, 4344904) using the SYBR Green (Roche, 04913914001). Signal was detected using a
Step One Plus Real-Time PCR System (Applied Biosystems). Target gene cycle numbers were normalized to the house keeping gene GAPDH to get a DCT value. The calculated equation is 2 -DDCT . The primers used in this study have been supplied in the Supporting Information Table 3 .
Statistical analysis
GraphPad Prism 6.0 software was used for the statistical analysis. Poisson distribution-based analysis was used to determine calculate the LSC frequencies in the limiting dilution experiments. A log-rank (Mantel-Cox) test was used to determine the p values for all Kaplan-Meier survival analyses (both mouse models and patients). One-way-ANOVA was used for all analyses when comparing more than two groups. Data are expressed as the mean 6 SEM. Values of p< 0.05 were considered to be statistically significant. The absence of * in the graphs indicates that there is no statistic difference between groups.
Results

PBX3 is specifically and highly expressed in LSCs of MLL-fusion induced leukemia
To investigate the potential role of PBX3 in leukemia, we analyzed the clinical database to assess its expression patterns in normal and malignant human hematopoietic cells (from the HemaExplorer database). We found that PBX3 is selectively up-regulated in MLL-r AML when compared with other AML subtypes as well as their normal counterparts (Fig. 1a) . Moreover, analysis of the published clinical data collected using PrognoScan revealed that high levels of PBX3 expression indicates a poor prognosis in AML patients (Supporting Information Fig. S1a) . [32] [33] [34] To further confirm relationship between PBX3 expression level and MLL-r leukemia, the Pbx3 expression patterns in AML mouse models induced by MLL-fusion genes was tested. Retrovirus-mediated ectopic expression of either MLL-AF9 or MLL-NRIP3 was used to transform murine BM progenitors (c-Kit
, and to establish the AML mouse models. Leukemia cells were isolated from moribund primary recipient mice and homogenized by serial transplantations (Supporting Information Fig. S1b ). We analyzed the expression of Pbx3 in LSCs (defined as L-GMP, or with the clinical data, Pbx3 is highly expressed in LSCs compared to normal HSPCs (Fig. 1b) . We also detected the expression levels of other homeobox genes and TALE family genes (which were reported to be up-regulated in MLL-r leukemia) in cells isolated from either AML or control mice. Normally, homeobox gene expression is high in hematopoietic stem cells and is gradually extinguished during differentiation. 36 The results showed that, except for Pbx3, other tested homeobox genes were both highly expressed in LSKs and LSCs, whereas only Pbx3 was specifically upregulated in LSCs compared with HSPCs or other normal hematopoietic cells (Fig. 1b, Supporting Information Fig. S1c) . Additionally, the MLL-r leukemia LSC maintenance-related genes Myb, Cbx5, Hmgb3 37 were also up-regulated in the LSCs of the MLL- One-way-ANOVA was used for comparing more than two groups, **p < 0.01, ***p < 0.001.
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Guo et al. Information Fig.  S1d ). Thus, these findings suggested a potential role of PBX3 in LSCs in both human MLL-r AML patients and MLL-r AML mouse models.
NRIP3-induced mouse model (Supporting
Aberrant epigenetic modifications are associated with the high expression level of PBX3 in LSCs
Previous studies demonstrated the presence of aberrant epigenetic modifications of MLL target genes such as HOXA9/ MEIS1 in MLL-r leukemia. 10 Here, we proposed that the epigenetic modification may be associated with the high expression of PBX3 in MLL-r leukemia. To test this, we analyzed the public ChIP-Seq data of H3K79me2, H3K4me3, H3K36me3 and H3K27me3 in L-GMPs from MLL-AF9 induced leukemic mice, as well as murine LSKs and GMPs from the GEO database. 10 Among the transcription-activating modifications such as H3K79me2, H3K4me3 and H3K36me3, only H3K79 showed significant hypermethylation along the Pbx3 gene body, which indicates an active state for elongation 9, 38 in L-GMPs compared with normal GMPs (Fig. 2a) . Moreover, different from the Hoxa clusters exhibiting high H3K79me2 levels in both LSKs and L-GMPs, 10 Pbx3 showed specific high levels of H3K79me2 in L-GMPs, suggesting an alternative regulatory mode of Pbx3 than the rest of the Hoxa clusters. This might explain why Pbx3 is selectively and highly expressed in LSCs other than LSKs or GMPs (Figs. 1b and 2a) . Furthermore, the transcription repressive mark H3K27me3 showed a decreased pattern in L-GMPs compared with normal HSPCs (Fig. 2a) . To further confirm these data, we assessed H3K79me2 modifications of Pbx3 by ChIP-qPCR in our AML mouse model. In whole BM we found that the H3K79me2 levels on PBX3 were increased in leukemic blast cells compared to normal BM (Fig. 2b) , which was correlated with its gene expression level (Fig. 2c) . Furthermore, we purified c-Kit 1 cells that were enriched for stem cells 9, 37 to assess the Pbx3 epigenetic modification patterns in LSCs and HSPCs. Consistently, ChIP-qPCR of c-Kit 1 cells from AML and normal mice revealed a similar trend with cells in the BM (Fig. 2e ) and the database analysis (Fig. 2a) . Unexpectedly, the transcription activation modification H3K4me3 was decreased in LSCs compared to HSPCs (Fig. 2d) , whereas database analysis showed that H3K4me3 was slightly increased at the promoter region of Pbx3 in L-GMPs compared to GMPs (Fig. 2a) . We also analyzed the repressive mark H3K9me3 on Pbx3 and found dramatically decreased H3K9me3 modifications in LSCs compared to HSPCs (Fig. 2f) . Bernt KM et al. identified MLL-AF9 fusion protein target genes via using biotin labeled MLL-AF9 followed by ChIP-Seq using streptavidin. 10 Here we re-analyzed their deposited ChIP-seq data of MLL-AF9 fusion protein in MLL-AF9 transformed cells. To our surprise, we found that different from MLL target genes like Hoxa9 and Meis1, Pbx3 seemed not to be directly targeted by MLL-AF9 (Supporting Information Fig. S2a ). To further investigate the regulation network between H3K79me2 and Pbx3, we treated MLL-AF9 leukemia cells with EPZ004777, an inhibitor of H3K79me2 methyltransferase DOT1L. The results showed that EPZ004777 significantly decreased the expression level of Pbx3 and inhibited leukemia cells growth (Supporting Information Figs. S2b-S2d) . Collectively, these results suggested that high expression levels of Pbx3 might be the result of elevated levels of the activation mark H3K79me2 and depressed levels of the repressive marks H3K27me3 and H3K9me3.
PBX3 inactivation significantly impedes leukemic progression in MLL-AF9 induced AML mouse model
Considering that the high expression level of PBX3 in LSCs may contribute to leukemic progression, we used the CRISPR/ Cas9 system to delete Pbx3 to investigate its role in MLL-AF9 mediated murine AML development. We designed two different sgRNAs targeting Pbx3 and cloned them into a lentiviral vector. This lentiviral vector contains U6 promoter-driven Pbx3 sgRNA and SFFV promoter-driven Cas9 with a fluorescent protein marker (mCherry) separated by a picorna virusderived 2A auto-cleavage site (P2A; Fig. 3a SgPBX3-a, SgPBX3-b or control mice to sub-lethally irradiated recipient mice, we found a significantly prolonged life span of MLL-AF9 leukemic mice transplanted with cells from downregulated Pbx3 groups (Fig. 3c) . The splenomegaly in MLL-AF9 leukemic mice was relieved in the Pbx3 inactivation group as evidenced by a remarkably smaller size and decreased spleen weight compared with the control group (Figs. 3d and  3e) . Furthermore, morphological analysis showed that more leukemic blast cells with segmented nuclei were present in the Pbx3 downregulated group, and flow cytometric analysis also showed increased expression of the myeloid differentiation antigen Gr-1 in the SgPBX3-a group (Fig. 3f , Supporting Information Figs. S3a and S3b), indicating that the loss of Pbx3 promoted the differentiation of MLL-AF9 leukemia cells. Additionally, the histology analysis showed reduced leukemic cells infiltration in liver, spleen, lung, spine and brain in Pbx3 inactivation groups, and the complete blood counting (CBC) also showed the decreased proliferation of white blood cells (WBC) in Pbx3 inactivation group, suggesting that Pbx3 inactivation delayed the leukemia progress (Supporting Information Figs. S3c and S3d, Supporting Information Table 2 ). Collectively, these data demonstrated that PBX3 is critical for maintaining a less differentiated AML phenotype and supporting the leukemic progression of MLL-r leukemia.
Pbx3 is required to sustain the LSC potential of MLL-AF9 AML cells
LSC was considered to be sufficient to drive leukemogenesis and maintain leukemia progression 2, 39 , therefore, we investigated the impact of Pbx3 inactivation on LSC capability. We used flow cytometry to analyze the LSC (K 1 G -) frequency in secondary recipient mice. We found a notable decrease in LSC frequency in the BM of Pbx3 inactivation recipients when compared to control mice (Figs. 4a and 4b) . At the same time, the LSC absolute number was also greatly reduced in the Pbx3 inactivation group (Fig. 4c) . Similarly, using another set of LSC marker-Lin The results showed that the Pbx3 inactivation groups formed significantly fewer colonies of total numbers and type A clones (Fig. 4f) . Cells from the colonies were replated every 6 days for three passages. The results showed that Pbx3 inactivation group formed significantly fewer colonies after one passage replating, especially in SgPbx3-b group (Fig. S4c) . Limiting dilution transplantation assays revealed that the frequency of LSCs in control leukemic bone marrow is 1/102 but was reduced to 1/442 in SgPBX3-a and 1/741 in SgPBX3-b, indicating a four to sevenfold decrease in the number of functional LSCs after Pbx3 inactivation (Fig. 4g,  Supporting Information Fig. S4b ).
Previous studies reported that PBX3 interacts with MEIS1 and acts as a critical cofactor of HOXA9 in leukemogenesis. 24, 26, 27 Here, we measured the Hoxa9 and Meis1 expression levels in L-GMPs. The results showed that Hoxa9 was Information Fig. S4c) , which is consistent with the reported role of PBX3 acting as a supportive cofactor of HOXA9 in LSC maintenance. Previous study demonstrated that PBX3 could stabilize MEIS1 protein and protect it from degradation, 26 and here we performed Western blotting to analyze MEIS1 protein stability after PBX3 inactivation. We found that MEIS1 protein was decreased after PBX3 inactivation, indicating that MEIS1 protein stabilization is depend on PBX3 (Fig. 3b, Supporting Information Fig. S4e ). In addition, an assessment of expression changes in a panel of LSC maintenance genes demonstrated that depletion of Pbx3 resulted in significant down-regulation of LSC maintenance genes, including Cbx5, Hmgb3 and Myb (Supporting Information  Fig. S4d ). The gene expression patterns observed here are also consistent with decreased function of LSCs in the Pbx3 inactivation group. Thus, our data indicated that a deficiency of Pbx3 reduced LSC numbers and impaired their function.
PBX3 maintains LSC of MLL-AF9 leukemia mainly by inhibiting apoptosis
As demonstrated above, Pbx3 inactivation prolonged leukemic mice survival and impaired LSC number and function. Thus, we investigated apoptosis and the cell cycle in AML cells to analyze the underlying cellular mechanisms of the observed phenotype. Analysis revealed more AML cells underwent apoptosis in the Pbx3 inactivation group, particularly LSCs (Figs. 5a-5c, Supporting Information Figs. S5a and S5b). Then, we analyzed cell cycle changes by Ki67 and Hoechst staining to discriminate the G0, G1 and S/G2/M phases. The staining showed that the loss of Pbx3 (SgPBX3-b) also reduced the frequency of actively proliferating LSCs, and more LSCs were arrested in G0 and G1 (Fig. 5e and Supporting Information Fig. S5d) . The leukemic blasts presented a similar phenotype in the SgPBX3-b group ( Fig. 5d and Supporting Information Fig. S5c ). Trp53 acts as tumor suppressor through the inhibition of cell cycle progression and the activation of apoptosis, and the latter is considered to be essential for its tumor suppressor ability. 40 To further investigate the potential cause of apoptosis changes, we examined the mRNA expressions of pro-apoptotic genes, including Trp53, Bax and Bim in LSCs. 41 We found that in LSCs of Pbx3 inactivation group, the mRNA expression level of Trp53 was significantly increased, and the Bax expression level was also slightly increased (Fig. 5f) . We also measured the protein level of Caspase3, a member of caspase family which plays a central role in the execution-phase of cell apoptosis, 42 and found that the activated Caspase3 (Cleaved Caspase3) is up-regulated in Pbx3 inactivation group (Fig. 5g) . These data suggested that the depletion of functional LSCs in the Pbx3 inhibition group is mainly due to acceleration of the apoptotic process by activating tumor suppressor Trp53 and classical apoptosis pathway in LSCs.
Discussion
In this study, we showed that the high expression levels of PBX3 in AML patients correlated with a poor prognosis. In the MLL-r mouse model, we found that aberrant modification of epigenetic networks with increased levels of the activation mark H3K79me2, accompanied by a decrease of the repressive marks H3K27me3 and H3K9me3 might be the reason for high expression levels of PBX3 in LSCs of MLL-r leukemia. Using CRISPR/Cas9-mediated Pbx3 deletion in murine MLL-AF9 leukemia cells, we found that Pbx3 inactivation delayed leukemia progression with a decrease in functional LSCs mainly by promoting LSC apoptosis. Our data uncover the aberrant epigenetic modification of PBX3 in LSCs and demonstrate a unique role of PBX3 in maintaining LSCs, suggesting PBX3 as a prospective prognosis marker and a likely pathological target in AML patients.
As an important member of the TALE family, PBX3 has been reported to protect HSC from exhaustion in the HSC active cycling context. 43 PBX3 also exhibited a significantly positive correlation with HOXA9 in AML. [24] [25] [26] 44, 45 Moreover, a recent study showed that co-expression of PBX3 and MEIS1 is sufficient for normal hematopoietic cell transformation. 27 All these studies suggested that TALE family members such as PBX3 and MEIS1 may have independent role(s) on leukemogenesis rather than just simply providing a supportive role in facilitating HOXA functioning (Fig. 6) . In our analysis, PBX3 is highly expressed in human MLL-r AMLs, and its high level of expression is associated with a poor prognosis in AML patients (Fig. 1a and Supporting Information Fig. S1a ). We also found that Pbx3 is selectively and highly expressed in LSCs in comparison with normal HSPCs in an AML murine model (Fig. 1b) , in accordance with the clinical data. Additionally, the ChIP-seq data of MLL-AF9 indicated that Pbx3 may not be MLL target genes as Hoxa9 and Meis1 (Supporting Information Fig. S2a) . Thus, the combined results suggested that PBX3 might play a unique role in MLL-r leukemia. PBX3 could form a dimer with MEIS1 to evoke the full transforming activity of HOXA9. 24, 26, 44 Enforced expression of any two of these three proteins could transform HSPCs to LSCs. 22, 24, 27 Increase in the activation marker H3K79me2 together with the reduction of the repressive markers H3K27me3 and H3K9me3 in transformed LSCs, promote the high expression of PBX3 in LSCs and the elevated PBX3 levels maintain LSC capacity and inhibit LSC apoptosis.
To explore why PBX3 is highly expressed specifically in LSCs, we analyzed epigenetic modification patterns along the Pbx3 gene. From database analysis, we found that, different from high levels of H3K79me2 on HOXA clusters in both LSKs and GMPs, 10 H3K79 hypermethylation of Pbx3 was only observed in L-GMPs but not in LSKs or GMPs, consistent with increased Pbx3 expression in LSCs in contrast to HSPCs. Furthermore, we assessed the H3K79me2, H3K4me3 and H3K9me3 methylation patterns of Pbx3 by ChIP-qPCR in purified c-Kit 1 cells enriched for stem cells from leukemic and control mice. One previous study reported that high level of H3K4me3 is crucial for the expression of LSC maintenance genes. 9 Consistent with this, database analysis showed slightly increased H3K4me3 on the promoter region of Pbx3 in L-GMPs when compared with GMPs. However, in our ChIP-qPCR analysis, H3K4me3 on Pbx3 in LSCs is lower than in HSPCs. This discrepancy could be caused by the use of stem cell marker c-Kit to purify the LSCs in our experiment versus LGMP used by others. Also, decreased H3K4me3 level in LSCs suggest a less involvement of H3K4me3 in regulating Pbx3 expression in our leukemia model. Additionally, we demonstrated that the repressive modification H3K9me3 is decreased in LSCs when compared with HSPCs. Collectively, increased modification of activating H3K79me2 combined with the reduced modification of the repressive H3K27me3 and H3K9me3 contributed to the high expression levels of Pbx3 in LSCs.
In a previous study, PBX3 was considered as a redundant contributor of MLL-fusion mediated cell transformation due to MLL-fusion oncoproteins displaying no significant difference of the transformation efficiency between PBX3-deficient and wild-type myeloid progenitors. 18 However, Li et al. found that PBX3 is necessary in MLL-fusion induced cell transformation by knocking-down PBX3 using shRNA. 24 Thus, these studies raise the issue as to whether PBX3 is required during MLL-r leukemia development and prompt us to assess the effect of an acute loss of PBX3 expression in fully developed leukemia. Here, we used the CRISPR/Cas9 system to eliminate Pbx3 and investigate its specific role in leukemia maintenance in an MLL-fusion induced AML mouse model. Our results clearly demonstrated that loss of Pbx3 prolonged the leukemic mice's life span and reduced their leukemic burden. Furthermore, we revealed that inactivation of Pbx3 compromise the LSC capacity mainly through reducing the LSC number and impairing their function. Thus, our data established a critic role of PBX3 in LSC maintenance.
In summary, the findings from our current study established an integrated paradigm of the epigenetic modification network of PBX3 and its independent regulatory role in LSC maintenance. Particularly, high level of active mark H3K79me2 in conjunction with a lower levels of the repressive marks H3K27me3 and H3K9me3 maintain the high expression level of PBX3 in LSCs. Active PBX3 prevents LSC apoptosis and maintains LSC capacity (see Fig. 6 ). Thus, the clarified regulation network of PBX3 lends itself as a potential prognostic marker as well as a possible therapeutic target to treat MLLfusion AML.
